Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer

Lei,Ke-Feng; Liu,Bing-Ya; Jin,Xiao-Long; Guo,Yan; Ye,Min; Zhu,Zheng-Gang

doi:10.3892/etm.2012.532

Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer

Authors:
- Ke-Feng Lei
- Bing-Ya Liu
- Xiao-Long Jin
- Yan Guo
- Min Ye
- Zheng-Gang Zhu
View Affiliations

Affiliations: Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China
Published online on: March 30, 2012 https://doi.org/10.3892/etm.2012.532
Pages: 993-998

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To assess the prognostic and predictive value of maspin expression for the clinical response to 5-fluorouracil (5-FU)-based chemotherapy in advanced gastric cancer (GC) patients, the expression of maspin in primary tumors from 127 patients with advanced GC was examined using immunohistochemistry. Of the 127 patients, 74 were treated with surgery alone and 53 received additional adjuvant 5-FU-based chemotherapy. Nuclear and cytoplasmic maspin expression was observed in 46.5 (59/127) and 68.5% (87/127) of patients, respectively. Nuclear maspin immunoreactivity was significantly associated with larger tumor size (p=0.036), the depth of tumor invasion (p=0.02) and lymph node metastasis (p=0.002). Cytoplasmic maspin immunoreactivity was associated with tumor cell differentiation but not with the other clinicopathological variables. Nuclear maspin immunoreactivity had a significant association with overall survival (OS). Among the nuclear maspin-expressing patients, those who were treated with 5-FU-based adjuvant chemotherapy showed significantly longer OS than those without chemotherapy (p=0.0004). In conclusion, nuclear maspin expression is associated with adverse clinical outcomes in patients with advanced GC. Patients with positive nuclear maspin expression may be more responsive to adjuvant 5-FU chemotherapy.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
2.	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006.
3.	Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001. View Article : Google Scholar
4.	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research Collaboration) Group; Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Zou Z, Anisowicz A, Hendrix MJ, et al: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
6.	Ogasawara S, Maesawa C, Yamamoto M, et al: Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene. 23:1117–1124. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Umekita Y, Ohi Y, Sagara Y, et al: Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer. 100:452–455. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Ohike N, Maass N, Mundhenke C, et al: Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett. 199:193–200. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Sood AK, Fletcher MS, Gruman LM, et al: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 8:2924–2932. 2002.PubMed/NCBI
10.	Kim SM, Cho SJ, Jang WY, et al: Expression of maspin is associated with the intestinal type of gastric adenocarcinoma. Cancer Res Treat. 37:228–232. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Song SY, Son HJ, Kim MH, et al: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology. 54:973–976. 2007.PubMed/NCBI
12.	Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.
13.	Boku N: Perspectives for personalization in chemotherapy of advanced gastric cancer. Discov Med. 9:84–89. 2010.PubMed/NCBI
14.	Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Won HJ, Ha TK, Kwon SJ, et al: Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells. Anticancer Drugs. 21:270–276. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol. 23:1365–1369. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist. 10(Suppl 3): 49–58. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Park DJ and Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol. 6:337–344. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Kubota T and Weisenthal L: Chemotherapy sensitivity and resistance testing: to be ‘standard’ or to be individualized, that is the question. Gastric Cancer. 9:82–87. 2006.
20.	Dietmaier W, Bettstetter M, Wild PJ, et al: Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer. 118:2247–2254. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Zheng Z, Li J, He X, et al: Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 57:1106–1112. 2010.PubMed/NCBI
22.	Sheng S, Truong B, Fredrickson D, et al: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA. 95:499–504. 1998. View Article : Google Scholar : PubMed/NCBI
23.	Dokras A, Gardner LM, Kirschmann DA, et al: The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta. 23:274–280. 2002. View Article : Google Scholar
24.	Shi HY, Zhang W, Liang R, et al: Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol. 18:201–206. 2003.PubMed/NCBI
25.	Zhang M, Volpert O, Shi YH, et al: Maspin is an angiogenesis inhibitor. Nat Med. 6:196–199. 2000. View Article : Google Scholar
26.	Mohsin SK, Zhang M, Clark GM, et al: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol. 199:432–435. 2003. View Article : Google Scholar : PubMed/NCBI
27.	Marioni G, Blandamura S, Giacomelli L, et al: Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology. 46:576–582. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Lee DY, Park CS, Kim HS, et al: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol. 16:13–18. 2008.PubMed/NCBI
29.	Ben Shachar B, Feldstein O, Hacohen D, et al: The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol Cancer Res. 8:363–372. 2010.PubMed/NCBI